Mission
IMBCR is dedicated to advance the treatment of myeloma by connecting possibility through scientific innovation leading to personalized and continuous optimized patient care.
Vision
IMBCR is committed to helping all patients with myeloma Live Better and Live Longer.
A unique and fully integrated research center, exploring innovative therapeutic approaches using laboratory-based research and sophisticated data analytics to advance clinical development. The Institute aims to improve and personalize patient care, optimizing outcomes and ultimately cure myeloma.
Three Pillars:
IMBCR research enables clinicians to identify the disease faster, optimize treatment plans, and provide the most effective therapy available. See how IMBCR Initiatives are accomplishing this.
Focus on Today
By combining analysis of big data technologies, genetics, and patient medical and treatment history, Precision Myeloma empowers doctors to give personalized care leading to longer survival, better treatment tolerability and ultimately a cure.
Help us develop this exciting new project.
Precision Care Quality of Life
Ultimately our goal is to eradicate myeloma and allow patients to continue to Live Better and Live Longer. IMBCR!
CURE MYELOMA PROJEC
Living Life Free of Myeloma
Current Initiatives
A Game-Changer in Myeloma Monitoring & Treatment
Total Funding Goal: $500,000
IMBCR scientists have discovered that the “i1”protein is a key indicator of myeloma progression. Specifically, we have shown that blood levels of this protein are elevated in myeloma patients and can be used to predict outcomes and monitor patients with this disease. We have shown that reducing levels of this protein knocks out myeloma.
Our laboratory has now developed compounds that prevent “i1” from functioning and shown that they eradicate myeloma in our laboratory studies! Our research team has shown that these compounds also help prevent the spread of myeloma and overcome the immune deficiency that is a hallmark of myeloma. We believe we are on the cusp of a revolutionary new therapy for myeloma patients. disease.
JAK inhibitors, a new class of drugs to treat multiple myeloma.
Total Funding Goal: $500,000
IMBCR has identified a new way to treat myeloma with drugs that are safe and well-tolerated. We have identified the immune boosting potential of these drugs as well as their ability to make other active multiple myeloma drugs more effective.
- Because of our research findings, new clinical trials are now being conducted to test these approaches for patients with myeloma and other types of cancer.
- IMBCR Impact:To build combinations of these drugs with already active multiple myeloma drugs and also enhance the effects of immune type agents to defeat the disease.
Testimonial: Today, patients with multiple myeloma want drugs that are easy to take, well tolerated, and work well. Finding drugs like the JAK Inhibitors, which accomplish this, is an important breakthrough for treatment of multiple myeloma. – Dr. James Berenson, IMBCR CEO and President
sBCMA
Total Funding Goal: $500,000
- sBCMA – a revolutionary blood marker allowing clinicians to follow and identify changes in the disease faster, enabling a more rapid way to determine how a patient is responding to therapy, and to optimize treatment plans.
- IMBCR Impact: To support optimized treatment plans based on earlier prediction of outcomes; switching to new therapies sooner and stop unnecessary and expensive medicines which may be causing undesirable side effects.
Testimonial: “We seek to further the development of the role of serum BCMA measurements with our collaboration with Dr. Berenson and his team of innovative and passionate scientists at IMBCR” said Dr. Stephen Harding, Chief Scientific Officer of The Binding Site Group.
Uncovering New Treatments for Multiple Myeloma
Total Funding Goal: $500,000
The aim of this project is to identify new drug candidates for treating multiple myeloma and also find novel combinations of already existing drugs to optimize patient outcomes.
Evidence of multiple myeloma with Silicone Gel Breast Implants
Total Funding Goal: $400,000
The average age of onset of multiple myeloma is in the late 60’s. However, there are a number of cases that have been identified in younger population of females (~ 30-55 years of age). One of the common features that these patients share is silicone gel breast implants.
- Our goal is to gather more evidence supporting this connection, to help reduce multiple myeloma in the female population.
- IMBCR IMPACT: This study will provide much needed education for women’s health and optimal lifestyle choices.
